KR102256919B1 - 혈액 항응고제로서 알기네이트 올리고머의 용도 - Google Patents

혈액 항응고제로서 알기네이트 올리고머의 용도 Download PDF

Info

Publication number
KR102256919B1
KR102256919B1 KR1020167019688A KR20167019688A KR102256919B1 KR 102256919 B1 KR102256919 B1 KR 102256919B1 KR 1020167019688 A KR1020167019688 A KR 1020167019688A KR 20167019688 A KR20167019688 A KR 20167019688A KR 102256919 B1 KR102256919 B1 KR 102256919B1
Authority
KR
South Korea
Prior art keywords
blood
residues
mer
alginate
alginate oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167019688A
Other languages
English (en)
Korean (ko)
Other versions
KR20160099707A (ko
Inventor
아르네 데센
필립 리에
Original Assignee
알지파마 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알지파마 에이에스 filed Critical 알지파마 에이에스
Publication of KR20160099707A publication Critical patent/KR20160099707A/ko
Application granted granted Critical
Publication of KR102256919B1 publication Critical patent/KR102256919B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A61M1/3673—Anticoagulant coating, e.g. Heparin coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167019688A 2013-12-20 2014-12-19 혈액 항응고제로서 알기네이트 올리고머의 용도 Active KR102256919B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322777.2A GB201322777D0 (en) 2013-12-20 2013-12-20 Use of alginate oligomers as blood anticoagulants
GB1322777.2 2013-12-20
PCT/GB2014/053808 WO2015092437A1 (en) 2013-12-20 2014-12-19 Use of alginate oligomers as blood anticoagulants

Publications (2)

Publication Number Publication Date
KR20160099707A KR20160099707A (ko) 2016-08-22
KR102256919B1 true KR102256919B1 (ko) 2021-05-27

Family

ID=50071308

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019688A Active KR102256919B1 (ko) 2013-12-20 2014-12-19 혈액 항응고제로서 알기네이트 올리고머의 용도

Country Status (18)

Country Link
US (1) US11712448B2 (https=)
EP (1) EP3082830B1 (https=)
JP (1) JP6626824B2 (https=)
KR (1) KR102256919B1 (https=)
CN (1) CN105960243B (https=)
AU (1) AU2014369463B2 (https=)
BR (1) BR112016014321A8 (https=)
CA (1) CA2934572C (https=)
DK (1) DK3082830T3 (https=)
ES (1) ES2779228T3 (https=)
GB (1) GB201322777D0 (https=)
HU (1) HUE048891T2 (https=)
PL (1) PL3082830T3 (https=)
PT (1) PT3082830T (https=)
RS (1) RS60124B1 (https=)
RU (1) RU2709814C1 (https=)
SI (1) SI3082830T1 (https=)
WO (1) WO2015092437A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017471B2 (en) * 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11072668B2 (en) 2017-01-03 2021-07-27 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7403152B2 (ja) 2017-03-28 2023-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景
AU2018369760B2 (en) 2017-11-15 2025-01-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7645546B2 (ja) 2018-12-28 2025-03-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法
GB201908639D0 (en) * 2019-06-17 2019-07-31 Algipharma Ipr As Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure
US20220251627A1 (en) * 2019-06-28 2022-08-11 Zymo Research Corporation Compositions for the stabilization of cell-free nucleic acids and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103977A1 (en) 2008-02-22 2009-08-27 Athera Biotechnologies Ab Compounds and methods for the prevention or treatment of restenosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2508433A (en) * 1946-10-16 1950-05-23 Wyeth Corp Alginic acid sulfate anticoagulant
DE3152319C2 (de) * 1980-09-03 1986-05-07 Kyosei Pharmaceutical Co., Ltd., Hokkaido Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera
US5135955A (en) * 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
KR920000459B1 (ko) 1989-12-13 1992-01-14 재단법인 한국화학연구소 다당류 유도체가 도포된 인공혈관과 그 제조방법
GB9221163D0 (en) 1992-10-08 1992-11-25 Nobipol And Protan Biopolymer Dna compounds
US5646130A (en) 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
NO305033B1 (no) 1997-05-09 1999-03-22 Algipharma As Fremgangsmate for fremstilling av uronsyreblokker fra alginat
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
NO20023581D0 (no) 2002-07-26 2002-07-26 Fmc Biopolymer As Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat
CN1218965C (zh) 2003-11-04 2005-09-14 武汉大学 海藻酸钠硫酸酯及其制备方法和用途
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
KR101472765B1 (ko) 2006-12-08 2014-12-15 밀레니엄 파머슈티컬스 인코퍼레이티드 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
KR101690631B1 (ko) * 2007-11-27 2017-01-09 알지파마 아이피알 에이에스 바이오필름 퇴치에 있어서의 알기네이트 올리고머의 용도
BRPI1011248A2 (pt) 2009-06-03 2016-03-22 Algipharma As métodos in vitro ou ex vivo de superação de resitência a pelo menos um antibiótico, para combate de contaminação de um sítio e melhora da eficácia de um antibiótico de macrolídeo para inibir o crescimento de bactéria mdr gram negativa, uso de um oligômero de alginato e produto
KR101229055B1 (ko) * 2010-06-07 2013-02-04 신라대학교 산학협력단 알긴산 분해능을 갖는 메틸로박테리움 속 균주 및 상기 균주를 이용한 알긴산 올리고머 제조방법
CN102212148B (zh) 2011-03-21 2013-07-17 中国海洋大学 一种静脉注射用抗血栓药及其制备方法和应用
CN102382204B (zh) 2011-08-31 2013-06-26 中国海洋大学 低分子量藻酸双酯钠及其制备方法和应用
CN103142539B (zh) 2013-03-21 2014-08-20 青岛正大海尔制药有限公司 一种藻酸双酯钠控释片及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103977A1 (en) 2008-02-22 2009-08-27 Athera Biotechnologies Ab Compounds and methods for the prevention or treatment of restenosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Botanica Marina. 1991. Vol.34, pp.429-432.

Also Published As

Publication number Publication date
CA2934572C (en) 2023-08-15
ES2779228T3 (es) 2020-08-14
AU2014369463B2 (en) 2020-02-27
EP3082830A1 (en) 2016-10-26
AU2014369463A1 (en) 2016-07-14
US11712448B2 (en) 2023-08-01
JP6626824B2 (ja) 2019-12-25
HUE048891T2 (hu) 2020-08-28
BR112016014321A2 (https=) 2017-08-08
WO2015092437A1 (en) 2015-06-25
DK3082830T3 (da) 2020-03-30
BR112016014321A8 (pt) 2020-06-02
KR20160099707A (ko) 2016-08-22
US20160331777A1 (en) 2016-11-17
CN105960243B (zh) 2020-01-14
SI3082830T1 (sl) 2020-07-31
RS60124B1 (sr) 2020-05-29
CA2934572A1 (en) 2015-06-25
GB201322777D0 (en) 2014-02-05
RU2709814C1 (ru) 2019-12-23
CN105960243A (zh) 2016-09-21
EP3082830B1 (en) 2020-03-04
RU2016126848A (ru) 2018-01-25
JP2017508716A (ja) 2017-03-30
PL3082830T3 (pl) 2020-06-29
PT3082830T (pt) 2020-04-08

Similar Documents

Publication Publication Date Title
KR102256919B1 (ko) 혈액 항응고제로서 알기네이트 올리고머의 용도
TW201731553A (zh) 導管封存溶液及導管封存療法
JPH02502006A (ja) 抗転移活性を有する硫酸化ポリサッカライド
JPS62502472A (ja) 骨格関節の炎症の治療用製剤
EP2121048A2 (en) Hemostatic compositions and therapeutic regimens
Yoon et al. Differential regeneration of myocardial infarction depending on the progression of disease and the composition of biomimetic hydrogel
Henning et al. Chitosan hydrogels significantly limit left ventricular infarction and remodeling and preserve myocardial contractility
JP2017508716A5 (https=)
US20030147848A1 (en) Use of n-desulfated heparin for treating or preventing inflammations
JPH08277224A (ja) 抗炎症剤
AU2003229881A1 (en) Methods of using lamellar bodies for therapeutic purposes
AU2020295693B2 (en) Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure
Al-Ansari et al. Low-molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs
HK1230504B (en) Use of alginate oligomers as blood anticoagulants
HK1230504A1 (en) Use of alginate oligomers as blood anticoagulants
CN104039331A (zh) 包含肝素的大分子结合物的用于处理血管的水溶液
JP2004507562A (ja) 抗血栓性組成物
Drozd et al. Hemorrhagic Activity of Cationic Starch Conjugates with Sterically Hindered Phenol after Intravenous Administration to Guinea Pigs
JP7657316B2 (ja) 血液凝固活性を有するペプチドとこの用途
JP4166851B2 (ja) 新規虚血・再灌流障害抑制剤
CN121926887A (zh) 一种菲牛蛭冻干粉及制备方法和用途
JP4460665B2 (ja) 生体吸収性薬物担体
CN112245413A (zh) 一种羟基酪醇对小鼠急性心肺损伤保护作用的方法
RU2388495C1 (ru) Способ получения тромборезистентных полимерных материалов
Alsharabasy Molecular Biological Studies to Evaluate the Treatment Role of Irradiated Scaffolds in Ulcers and Wounds in Rat Skin (Master Thesis)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5